Assessment of HER2 status in breast cancer biopsies is not affected by accelerated tissue processing.

Autor: Bulte JP; Department of General Surgery, Radboud University Medical Center, Nijmegen, the Netherlands., Halilovic A; Department of Pathology, Radboud University Medical Center, Nijmegen, the Netherlands., Kalkman S; Department of Pathology, University Medical Center Utrecht, Utrecht, the Netherlands., van Cleef PHJ; Department of Pathology, Radboud University Medical Center, Nijmegen, the Netherlands., van Diest PJ; Department of Pathology, University Medical Center Utrecht, Utrecht, the Netherlands., Strobbe LJA; Department of Surgical Oncology, Canisius-Wilhelmina Hospital, Nijmegen, the Netherlands., de Wilt JHW; Department of General Surgery, Radboud University Medical Center, Nijmegen, the Netherlands., Bult P; Department of Pathology, Radboud University Medical Center, Nijmegen, the Netherlands.
Jazyk: angličtina
Zdroj: Histopathology [Histopathology] 2018 Jul; Vol. 73 (1), pp. 81-89. Date of Electronic Publication: 2018 Apr 24.
DOI: 10.1111/his.13507
Abstrakt: Aims: To establish whether core needle biopsy (CNB) specimens processed with an accelerated processing method with short fixation time can be used to determine accurately the human epidermal growth factor receptor 2 (HER2) status of breast cancer.
Methods and Results: A consecutive case-series from two high-volume breast clinics was created. We compared routine HER2 immunohistochemistry (IHC) assessment between accelerated processing CNB specimens and routinely processed postoperative excision specimens. Additional amplification-based testing was performed in cases with equivocal results. The formalin fixation time was less than 2 h and between 6 and 72 h, respectively. Fluorescence in-situ hybridisation and multiplex ligation-dependent probe amplification were used for amplification testing. One hundred and forty-four cases were included, 15 of which were HER2-positive on the routinely processed excision specimens. On the CNB specimens, 44 were equivocal on IHC and required an amplification-based test. Correlation between the CNB specimens and the corresponding excision specimens was high for final HER2 status, with an accuracy of 97% and a kappa of 0.85.
Conclusions: HER2 status can be determined reliably on CNB specimens with accelerated processing time using standard clinical testing methods. Using this accelerated technology the minimum 6 h of formalin fixation, which current guidelines consider necessary, can be decreased safely. This allows for a complete and expedited histology-based diagnosis of breast lesions in the setting of a one-stop-shop, same-day breast clinic.
(© 2018 The Authors. Histopathology Published by John Wiley & Sons Ltd.)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje